Home・Listă Acțiuni・Ocular Therapeutix Inc

Ocular Therapeutix Inc

Închisă

SectorSănătate

9.17 4.8

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

9.09

Maxim

9.18

Indicatori cheie
By Trading Economics
Venit	9.8M -79M
Vânzări	2.7M 13M
EPS	-0.35
Marjă de profit	-584.512
Angajați	325
EBITDA	8.6M -76M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+180.52% upside

Dividende
By Acuity
Următoarele câștiguri	3 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-47M 1.8B
Deschiderea anterioară	4.37
Închiderea anterioară	9.17

Sentimentul știrilor

By Acuity

34%

66%

75 / 340 Clasament în Healthcare

Ocular Therapeutix Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6 aug. 2026, 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

5 aug. 2026, 21:03 UTC

Ocular Therapeutix Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains under pressure.

3 aug. 2026, 20:06 UTC

Social Media

News

Ocular Therapeutix shares rise after reporting Q2 revenue of $13.5 million, exceeding estimates, and announcing plans for a new drug application for AXPAXLI.

31 iul. 2026, 21:01 UTC

Ocular Therapeutix Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid rising inflation concerns.

30 iul. 2026, 19:39 UTC

Ocular Therapeutix shares are higher today, continuing an upward trend since Wednesday. The U.S. Dollar Index decline may be influencing broader market dynamics.

28 iul. 2026, 19:06 UTC

News

Ocular Therapeutix shares are lower amid broader market volatility and regulatory challenges, reaching a session low earlier today.

27 iul. 2026, 21:01 UTC

Ocular Therapeutix Inc. shares are higher in after-market trading, reaching a peak shortly after the session began amid improved European market sentiment.

22 iul. 2026, 18:36 UTC

Social Media

Ocular Therapeutix is presenting at the HC Wainwright conference, but shares are declining and remain below their 20-day moving average.

21 iul. 2026, 23:41 UTC

Ocular Therapeutix Inc shares rose in after-market trading, reaching their highest cumulative return of the day. The stock remains below its 20-day moving average.

20 iul. 2026, 19:46 UTC

Social Media

Ocular Therapeutix shares are lower today, continuing a downward trend. Early gains were followed by a pullback amid uncertain investor sentiment.

Comparație

Modificare preț

Ocular Therapeutix Inc Așteptări

Obiectiv de preț

By TipRanks

180.52% sus

Prognoză pe 12 luni

Medie 25.78 USD 180.52%

Maxim 31 USD

Minim 18 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcular Therapeutix Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Ocular Therapeutix Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

75 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.